Paragard Shortage: What Providers and Prescribers Need to Know in 2026

Paragard (intrauterine copper contraceptive, CooperSurgical) remains the most-prescribed hormone-free IUD in the United States and a cornerstone of reproductive healthcare. But in 2026, prescribers are navigating a complex landscape: no formal FDA shortage, ongoing mass tort litigation, growing patient demand for non-hormonal contraception, and a new competitor device (Miudella) entering the market. This guide summarizes what you need to know to manage your inventory, counsel patients effectively, and maintain continuity of care.

Current Availability Status (2026)

Paragard is not listed on the FDA Drug Shortage Database as of 2026. CooperSurgical continues manufacturing the TCu380A device and distributing through established channels. The device is ordered via CPT 58300 (insertion) and J-code J7300 (device), and can be billed under both medical and pharmacy benefits depending on the payer.

However, practical access challenges persist at the practice level:

Some distributors report intermittent inventory fluctuations

Practices in rural or underserved areas may have limited distributor access

Litigation uncertainty has prompted a subset of providers to reduce stocking or defer insertions

Increased patient demand for hormone-free contraception is outpacing routine inventory planning at some practices

The Paragard MDL: What Prescribers Need to Know

MDL No. 2974 — In Re: Paragard IUD Products Liability Litigation — involves allegations that the Paragard device can fracture or fragment during removal, causing injury. As of 2026:

Nearly 3,900 cases are active in the MDL in federal court

The first bellwether trial resulted in a defense verdict for CooperSurgical

A second bellwether trial is scheduled for Fall 2026

The FDA has not issued a recall or required additional black box warnings

More than 7,000 adverse event reports related to Paragard breakage have been filed with the FDA

Clinical recommendation: Providers should document informed consent discussions thoroughly, including the known risk of device fragmentation during removal. Current ACOG guidance does not recommend prophylactic removal in asymptomatic patients.

Counseling Patients on Paragard Access Challenges

When patients inquire about Paragard and your practice doesn't have it in stock, a structured response maintains trust and continuity:

Set expectations proactively. Notify patients at appointment booking that same-day insertion depends on current stock, and offer to order specifically for their visit.

Discuss Miudella as a copper IUD alternative. Approved in February 2025, Miudella is a hormone-free copper IUD with a smaller insertion device and less copper. It may be preferred by some patients who want hormone-free contraception and are concerned about heavy bleeding.

Bridge contraception. For patients needing immediate contraception while waiting for Paragard, recommend barrier methods or progestin-only pills as a bridge.

Refer to Planned Parenthood or Title X clinics. If your practice has prolonged inventory issues, reproductive health clinics may have shorter timelines.

Inventory Management Recommendations for Practices

Maintain a standing order with your distributor or specialty pharmacy for Paragard to prevent gaps

Consider stocking Miudella alongside Paragard to offer patients a choice of copper IUDs

Train staff to verify device availability when booking IUD insertion appointments

If ordering delays are frequent, build a 2–4 week buffer stock for anticipated demand

How medfinder Supports Your Patients

When your practice doesn't have Paragard in stock, you can direct patients to medfinder for providers. medfinder calls nearby pharmacies and clinics to find which ones have Paragard available, then texts results to the patient. This reduces patient frustration and prevents them from going without contraception while searching on their own.

For a full provider workflow, see: How to Help Your Patients Find Paragard in Stock: A Provider's Guide.